



## **New York State Medicaid Drug Utilization Review Board Meeting Agenda**

The Drug Utilization Review (DUR) Board will meet on February 14, 2019, from 9:00 a.m. to 4:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

### **Agenda Items**

#### **A. Drug Cap Reviews**

The DUR Board will review clinical and financial information for the following drug which has been identified as contributing to pharmacy expenditures exceeding the Medicaid Drug Cap (*NYS Public Health Law, Section 280*) and if applicable, recommend a supplemental rebate target amount:

1. Remicade (infliximab)

#### **B. Drug Utilization Reviews**

The DUR Board will review the following pharmacotherapies and recommend clinical criteria and/or interventions to ensure appropriate utilization:

1. Gabapentin/pregabalin and opioid concurrent utilization.

#### **C. Clinical Edit Reviews**

The DUR Board will be presented with utilization information associated with current clinical criteria and/or interventions:

1. Pharmacy management initiatives associated with pain management including opioids and medications used for opioid dependence.

#### **D. Pharmacy Utilization/Program Updates**

The DUR Board will be provided updates on the following topics:

1. Medications used for the prevention of migraine headaches and concurrent serotonin receptor agonist (triptans) utilization.
2. Systemic Immunomodulators utilization and corresponding diagnosis.

**Agenda Timeline** (subject to change based on meeting proceedings)

9:00 - 9:15	Welcome and Opening Comments
9:15 - 10:15	Public Comment Period
10:15 - 12:15	Drug Cap Reviews
12:15 - 1:45	Lunch/Executive Session (review of financial information)
1:45 - 2:45	Drug Utilization Reviews
2:45 - 3:15	Clinical Edit Reviews
3:15 - 3:45	Pharmacy Utilization/Program Updates
3:45 - 4:00	Final Comments and Adjournment

Interested parties must notify the Department of Health (DOH) by February 6, 2019 of their request to address the DUR Board during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing [dur@health.ny.gov](mailto:dur@health.ny.gov). (Please reference DUR Board Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes) and the total comment period will not exceed sixty (60) minutes. DOH reserves the right to limit the number of interested parties providing public comment in order to meet meeting timelines and accomplish meeting objectives.

Clinical information must be submitted in an electronic format by January 30, 2019 or the DUR Board may not have ample time to review the information.

All written statements must be received in an electronic format by February 6, 2019. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Any information regarding the DUR Board must be sent to the DOH to ensure distribution to all members. Interested parties should not contact or send any information directly to DUR Board members.